Mandate

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").

The facility is located in Strängnäs and provides specialised expertise and comprehensive services, supporting the development and manufacturing of oral solids and with specialist infrastructure for beta-lactam production. APL, which is now acquiring the facility, is a wholly state-owned company with a social mission to develop and provide a medically appropriate and quality-assured range of extemporaneous medicines and stock preparations. The acquisition is an important step for the Swedish government in strengthening Sweden's preparedness and ensuring access to essential medicines in Sweden, particularly in crisis situations.

Read more on the Government's website here.

Vinge's team consisted of among others Jonas Bergström, Per Kling and Ellenor Eckerborn (M&A), Mathilda Persson and Siri Blomberg (Corporate Commercial), Åsa Hellstadius and Ian Jonson (Life Science).

Related

Vinge advises parts of the consortium in connection with the public takeover offer for Cint

The public takeover offer was announced by a consortium consisting of Triton Fund 6, Bolero, Patrick Comer and Brett Schnittlich. The offer values all shares in Cint at approximately SEK 1,989 million. The shares in Cint are listed on Nasdaq Stockholm, Mid Cap.
April 27, 2026

Nordea and SEB enters into a SEK 2,000,000,000 credit facility agreement

On 22 April 2026, Nordea and SEB entered into a credit facility agreement in the aggregate amount of SEK 2,000,000,000 (with an accordion option for an additional SEK 400,000,000) with Humble Group AB (publ).
April 27, 2026

Vinge has advised Northmill in connection with its inaugural issuance of primary capital instruments (AT1)

Vinge has advised Northmill Group AB in connection with its issuance of SEK 275 million primary capital instruments (so called “AT1 bonds”) with a floating rate interest of 3-month STIBOR + 690 basis points. The AT1 bonds are perpetual with a first call option after five years and are intended to be admitted to trading on Nasdaq Transfer Market and, subsequently, on Nasdaq Stockholm.
April 27, 2026